Natural antibodies play a fundamental role in anti-cancer immunity.

The dominant targets of host immune response to malaria are repeat elements, which are short stretches of amino acids repeated within Plasmodium falciparum proteins, and these are associated with short-lived and exposure-dependent antibody responses.

Glycans play an important role in modulating the interactions between natural killer cells and antibodies to fight pathogens and harmful cells.

Red blood cells infected by the malaria parasite Plasmodium falciparum are destroyed by human natural killer cells in the presence of antibodies from people who have acquired clinical immunity to malaria.

A fully synthetic library of humanized single domain antibodies yields in vitro high affinity antibodies usable in cell biology and translational projects.

Non-neutralizing antibodies to the SARS-CoV-2 spike protein’s S2 domain that also recognize widely circulating endemic coronavirus strains are rapidly boosted by natural infection but not vaccination with stabilized spike-based vaccines.

SARS-CoV-2 spike variants that resist neutralization by therapeutic antibodies or convalescent plasma can be generated in the laboratory and exist at low frequency in natural populations.

Cutaneous papillomaviruses potentially escape humoral immune response by synthesizing an alternative major capsid protein isoform during the initial course of infection that is unable to induce neutralizing antibodies.

SARS-CoV-2 infection and vaccination elicit antibodies that cross-react with other human coronavirus spike proteins, indicating the spike S2 subdomain as a potential target strategy to develop a pan-coronavirus vaccine.

SARS-CoV-2 host-shutoff inhibits innate NK surveillance by suppressing activating ligands, however ADCC provides a potent NK stimulus that is mediated by antibodies targeting Nucleocapsid, ORF3a, and Membrane, with those targeting Spike being significantly weaker.